D. Louis, MOLECULAR PATHOLOGY OF MALIGNANT GLIOMAS, Annual Review of Pathology: Mechanisms of Disease, vol.1, issue.1, pp.97-117, 2006.
DOI : 10.1146/annurev.pathol.1.110304.100043

D. Ricard, A. Idbaih, F. Ducray, M. Lahutte, K. Hoang-xuan et al., Primary brain tumours in adults, The Lancet, vol.379, issue.9830, pp.1984-96, 2012.
DOI : 10.1016/S0140-6736(11)61346-9

A. Cohen, S. Holmen, and H. Colman, IDH1 and IDH2 Mutations in Gliomas, Current Neurology and Neuroscience Reports, vol.2012, issue.2, pp.1-7, 2013.
DOI : 10.1155/2012/469592

K. Walsh, J. Wiencke, D. Lachance, J. Wiemels, A. Molinaro et al., Telomere maintenance and the etiology of adult glioma, Neuro-Oncology, vol.17, issue.11, p.1445, 2015.
DOI : 10.1093/neuonc/nov082

H. Wang, T. Xu, Y. Jiang, H. Xu, Y. Yan et al., The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas, Neoplasia, vol.17, issue.3, pp.239-55, 2015.
DOI : 10.1016/j.neo.2015.02.002

R. Stupp, M. Hegi, W. Mason, M. Van-den-bent, M. Taphoorn et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, The Lancet Oncology, vol.10, issue.5, pp.459-66, 2009.
DOI : 10.1016/S1470-2045(09)70025-7

R. Stupp, W. Mason, M. Van-den-bent, M. Weller, B. Fisher et al., Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, New England Journal of Medicine, vol.352, issue.10, pp.987-96, 2005.
DOI : 10.1056/NEJMoa043330

N. Bleehen and S. Stenning, A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma, British Journal of Cancer, vol.64, issue.4, pp.769-74, 1991.
DOI : 10.1038/bjc.1991.396

A. Grosu, W. Weber, M. Franz, S. Stärk, M. Piert et al., Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy, International Journal of Radiation Oncology*Biology*Physics, vol.63, issue.2, pp.511-520, 2005.
DOI : 10.1016/j.ijrobp.2005.01.056

T. Khalil, J. Lemaire, V. Dedieu, and D. Donnarieix, MRI tumor response and clinical outcomes after LINAC radiosurgery on 50 patients with recurrent malignant gliomas, J Radiosurgery SBRT, vol.4, pp.291-305, 2013.

J. Mckenzie, J. Guarnaschelli, A. Vagal, R. Warnick, and J. Breneman, Hypofractionated stereotactic radiotherapy for unifocal and multifocal recurrence of malignant gliomas, Journal of Neuro-Oncology, vol.27, issue.28, pp.403-412, 2013.
DOI : 10.1200/JCO.2008.19.8721

D. Vordermark, O. Kölbl, K. Ruprecht, G. Vince, K. Bratengeier et al., Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma, BMC Cancer, vol.91, issue.1, p.55, 2005.
DOI : 10.1053/ctrv.2000.0191
URL : https://bmccancer.biomedcentral.com/track/pdf/10.1186/1471-2407-5-55?site=bmccancer.biomedcentral.com

G. Yazici, M. Cengiz, G. Ozyigit, G. Eren, F. Yildiz et al., Hypofractionated stereotactic reirradiation for recurrent glioblastoma, Journal of Neuro-Oncology, vol.85, issue.9, pp.117-140, 2014.
DOI : 10.1093/jnci/85.9.704

S. Stylli, R. Luwor, T. Ware, F. Tan, and A. Kaye, Mouse models of glioma, Journal of Clinical Neuroscience, vol.22, issue.4, pp.619-645, 2015.
DOI : 10.1016/j.jocn.2014.10.013

V. Marx, Models: stretching the skills of cell lines and mice, Nature Methods, vol.11, issue.6, pp.617-637, 2014.
DOI : 10.1073/pnas.1222878110

D. Hayes, Biomarker validation and testing, Molecular Oncology, vol.31, issue.5, pp.960-966, 2015.
DOI : 10.1200/JCO.2013.50.9984
URL : https://doi.org/10.1016/j.molonc.2014.10.004

N. Henry and D. Hayes, Cancer biomarkers, Molecular Oncology, vol.25, issue.2, pp.140-146, 2012.
DOI : 10.1200/JCO.2006.09.2775

R. Gallagher and V. Espina, Reverse Phase Protein Arrays: Mapping the Path Towards Personalized Medicine, Molecular Diagnosis & Therapy, vol.25, issue.8, pp.619-649, 2014.
DOI : 10.1038/nbt1329
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732707/pdf

J. Hughes, S. Rees, S. Kalindjian, and K. Philpott, Principles of early drug discovery, British Journal of Pharmacology, vol.4, issue.6, pp.1239-1288, 2011.
DOI : 10.1177/108705719900400206
URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2010.01127.x/pdf

M. Masuda and T. Yamada, Signaling pathway profiling by reverse-phase protein array for personalized cancer medicine, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, vol.1854, issue.6, pp.651-658, 1854.
DOI : 10.1016/j.bbapap.2014.10.014

R. Akbani, K. Becker, N. Carragher, T. Goldstein, L. De-koning et al., Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report, Molecular & Cellular Proteomics, vol.18, issue.7, pp.1625-1668, 2014.
DOI : 10.1093/bioinformatics/btq182

T. Helleday, E. Petermann, C. Lundin, B. Hodgson, and R. Sharma, DNA repair pathways as targets for cancer therapy, Nature Reviews Cancer, vol.265, issue.3, pp.193-204, 2008.
DOI : 10.1016/j.mrfmmm.2006.02.001

E. Chautard, G. Loubeau, A. Tchirkov, J. Chassagne, C. Vermot-desroches et al., Akt signaling pathway: a target for radiosensitizing human malignant glioma, Neuro-Oncol, vol.12, pp.434-477, 2010.
URL : https://hal.archives-ouvertes.fr/hal-01636179

P. Maier, L. Hartmann, F. Wenz, and C. Herskind, Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization, International Journal of Molecular Sciences, vol.62, issue.1, p.102, 2016.
DOI : 10.2217/fon.14.175
URL : http://www.mdpi.com/1422-0067/17/1/102/pdf

M. Nyati, M. Morgan, F. Feng, and T. Lawrence, Integration of EGFR inhibitors with radiochemotherapy, Nature Reviews Cancer, vol.38, issue.11, pp.876-85, 2006.
DOI : 10.1200/JCO.2005.16.584

S. Burdak-rothkamm, K. Rothkamm, K. Mcclelland, A. Rashid, S. Prise et al., BRCA1, FANCD2 and Chk1 are potential molecular targets for the modulation of a radiation-induced DNA damage response in bystander cells, Cancer Letters, vol.356, issue.2, pp.454-61, 2015.
DOI : 10.1016/j.canlet.2014.09.043

F. Tang and W. Loke, Molecular mechanisms of low dose ionizing radiation-induced hormesis, adaptive responses, radioresistance, bystander effects, and genomic instability, International Journal of Radiation Biology, vol.68, issue.2, pp.13-27, 2015.
DOI : 10.1158/0008-5472.CAN-07-5278

M. Bai, X. Ma, X. Li, X. Wang, Q. Mei et al., The Accomplices of NF-κB Lead to Radioresistance, Current Protein & Peptide Science, vol.16, issue.4, pp.279-94, 2015.
DOI : 10.2174/138920371604150429152328

A. Satelli and S. Li, Vimentin in cancer and its potential as a molecular target for cancer therapy, Cellular and Molecular Life Sciences, vol.50, issue.6, pp.3033-3079, 2011.
DOI : 10.1146/annurev.pharmtox.010909.105547

P. Leuraud, L. Taillandier, L. Aguirre-cruz, J. Medioni, E. Crinière et al., Correlation between genetic alterations and growth of human malignant glioma xenografted in nude mice, British Journal of Cancer, vol.84, issue.12, pp.2327-2359, 2003.
DOI : 10.1002/(SICI)1097-0215(19990420)84:2<150::AID-IJC10>3.0.CO;2-#

S. Troncale, A. Barbet, L. Coulibaly, E. Henry, B. He et al., NormaCurve: A SuperCurve-Based Method That Simultaneously Quantifies and Normalizes Reverse Phase Protein Array Data, PLoS ONE, vol.27, issue.6, p.38686, 2012.
DOI : 10.1371/journal.pone.0038686.s006
URL : http://doi.org/10.1371/journal.pone.0038686

J. Biau, E. Chautard, F. Court, B. Pereira, P. Verrelle et al., Global Conservation of Protein Status between Cell Lines and Xenografts, Translational Oncology, vol.9, issue.4, pp.313-334, 2016.
DOI : 10.1016/j.tranon.2016.05.005
URL : https://hal.archives-ouvertes.fr/hal-01643043

M. Prados, S. Chang, N. Butowski, R. Deboer, R. Parvataneni et al., Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma, Journal of Clinical Oncology, vol.27, issue.4, pp.579-84, 2009.
DOI : 10.1200/JCO.2008.18.9639

O. Chinot, W. Wick, W. Mason, R. Henriksson, F. Saran et al., Bevacizumab plus Radiotherapy???Temozolomide for Newly Diagnosed Glioblastoma, New England Journal of Medicine, vol.370, issue.8, pp.709-731, 2014.
DOI : 10.1056/NEJMoa1308345
URL : http://umu.diva-portal.org/smash/get/diva2:725879/FULLTEXT01

P. Gutin, F. Iwamoto, K. Beal, N. Mohile, S. Karimi et al., Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas, International Journal of Radiation Oncology*Biology*Physics, vol.75, issue.1, pp.156-63, 2009.
DOI : 10.1016/j.ijrobp.2008.10.043

F. Couñago, A. Rodríguez, P. Calvo, J. Luna, J. Monroy et al., Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society), Clinical and Translational Oncology, vol.34, issue.7, pp.31-43, 2017.
DOI : 10.1200/JCO.2015.63.9443

J. Bonner, P. Harari, J. Giralt, N. Azarnia, D. Shin et al., Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck, New England Journal of Medicine, vol.354, issue.6, pp.567-78, 2006.
DOI : 10.1056/NEJMoa053422

L. Kollar and R. Rengan, Stereotactic Body Radiotherapy, Seminars in Oncology, vol.41, issue.6, pp.776-89, 2014.
DOI : 10.1053/j.seminoncol.2014.09.022

C. Rubio, R. Morera, O. Hernando, T. Leroy, and S. Lartigau, Extracranial stereotactic body radiotherapy. Review of main SBRT features and indications in primary tumors, Reports of Practical Oncology & Radiotherapy, vol.18, issue.6, pp.387-96, 2013.
DOI : 10.1016/j.rpor.2013.09.009

N. De-vries, J. Beijnen, and O. Van-tellingen, High-grade glioma mouse models and their applicability for preclinical testing, Cancer Treatment Reviews, vol.35, issue.8, pp.714-737, 2009.
DOI : 10.1016/j.ctrv.2009.08.011

E. Fomchenko and E. Holland, Mouse Models of Brain Tumors and Their Applications in Preclinical Trials, Clinical Cancer Research, vol.12, issue.18, pp.5288-97, 2006.
DOI : 10.1158/1078-0432.CCR-06-0438

P. Workman, E. Aboagye, F. Balkwill, A. Balmain, G. Bruder et al., Guidelines for the welfare and use of animals in cancer research, British Journal of Cancer, vol.63, issue.11, pp.1555-77, 2010.
DOI : 10.1101/gad.1771409

E. Markova, S. Vasilyev, and I. Belyaev, 53BP1 foci as a??marker of tumor cell radiosensitivity, Neoplasma, vol.62, issue.05, pp.770-776, 2015.
DOI : 10.4149/neo_2015_092

A. Menegakis, C. Von-neubeck, A. Yaromina, H. Thames, S. Hering et al., ??H2AX assay in ex vivo irradiated tumour specimens: A novel method to determine tumour radiation sensitivity in patient-derived material, Radiotherapy and Oncology, vol.116, issue.3, pp.473-482, 2015.
DOI : 10.1016/j.radonc.2015.03.026

H. Meyer and C. Weihl, The VCP/p97 system at a glance: connecting cellular function to disease pathogenesis, Journal of Cell Science, vol.127, issue.18, pp.3877-83, 2014.
DOI : 10.1242/jcs.093831

N. Jiang, Y. Shen, X. Fei, K. Sheng, P. Sun et al., Valosin-containing protein regulates the proteasome-mediated degradation of DNA-PKcs in glioma cells, Cell Death and Disease, vol.11, issue.5, p.647, 2013.
DOI : 10.1038/nprot.2006.339

M. Livingstone, H. Ruan, J. Weiner, K. Clauser, P. Strack et al., in Response to DNA Damage, Cancer Research, vol.65, issue.17, pp.7533-7573, 2005.
DOI : 10.1158/0008-5472.CAN-04-3729

H. Zhang, Q. Wang, K. Kajino, and M. Greene, VCP, a Weak ATPase Involved in Multiple Cellular Events, Interacts Physically with BRCA1 in the Nucleus of Living Cells, DNA and Cell Biology, vol.19, issue.5, pp.253-63, 2000.
DOI : 10.1089/10445490050021168

K. Acs, M. Luijsterburg, L. Ackermann, F. Salomons, T. Hoppe et al., The AAA-ATPase VCP/p97 promotes 53BP1 recruitment by removing L3MBTL1 from DNA double-strand breaks, Nature Structural & Molecular Biology, vol.263, issue.12, pp.1345-50, 2011.
DOI : 10.1016/S0378-1119(00)00579-5

M. Meerang, D. Ritz, S. Paliwal, Z. Garajova, M. Bosshard et al., The ubiquitin-selective segregase VCP/p97 orchestrates the response to DNA double-strand breaks, Nature Cell Biology, vol.4, issue.11, pp.1376-82, 2011.
DOI : 10.1371/journal.pgen.1000110

S. Bao, Q. Wu, R. Mclendon, Y. Hao, Q. Shi et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature, vol.8, issue.7120, pp.756-60, 2006.
DOI : 10.1038/nn1473

H. Ohgaki and P. Kleihues, Genetic Pathways to Primary and Secondary Glioblastoma, The American Journal of Pathology, vol.170, issue.5, pp.1445-53, 2007.
DOI : 10.2353/ajpath.2007.070011
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1854940/pdf

D. Luca, A. Carotenuto, A. Rachiglio, A. Gallo, M. Maiello et al., The role of the EGFR signaling in tumor microenvironment, Journal of Cellular Physiology, vol.94, issue.3, pp.559-67, 2008.
DOI : 10.1016/S0002-9440(10)63772-8

S. Palumbo, P. Tini, M. Toscano, G. Allavena, F. Angeletti et al., Combined EGFR and Autophagy Modulation Impairs Cell Migration and Enhances Radiosensitivity in Human Glioblastoma Cells, Journal of Cellular Physiology, vol.41, issue.11, pp.1863-73, 2014.
DOI : 10.1093/abbs/gmp028

A. Thorne, C. Zanca, and F. Furnari, Epidermal growth factor receptor targeting and challenges in glioblastoma, Neuro-Oncology, vol.18, issue.7, p.914, 2016.
DOI : 10.1093/neuonc/nov319
URL : https://academic.oup.com/neuro-oncology/article-pdf/18/7/914/6838926/nov319.pdf

A. Chakravarti, M. Wang, H. Robins, T. Lautenschlaeger, W. Curran et al., RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients, International Journal of Radiation Oncology*Biology*Physics, vol.85, issue.5, pp.1206-1217, 2013.
DOI : 10.1016/j.ijrobp.2012.10.008